Surface Oncology, Inc. (SURF): Price and Financial Metrics


Surface Oncology, Inc. (SURF)

Today's Latest Price: $7.75 USD

0.11 (-1.40%)

Updated Nov 24 4:00pm

Add SURF to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

SURF Stock Summary

  • Surface Oncology Inc's stock had its IPO on April 19, 2018, making it an older stock than just 7.53% of US equities in our set.
  • As for revenue growth, note that SURF's revenue has grown 58.12% over the past 12 months; that beats the revenue growth of 91.15% of US companies in our set.
  • The volatility of Surface Oncology Inc's share price is greater than that of 92.07% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to SURF, based on their financial statements, market capitalization, and price volatility, are ALPN, CKPT, SRRK, FPRX, and SGMO.
  • SURF's SEC filings can be seen here. And to visit Surface Oncology Inc's official web site, go to www.surfaceoncology.com.

SURF Stock Price Chart Interactive Chart >

Price chart for SURF

SURF Price/Volume Stats

Current price $7.75 52-week high $10.25
Prev. close $7.86 52-week low $1.38
Day low $7.60 Volume 493,800
Day high $7.85 Avg. volume 1,037,633
50-day MA $8.04 Dividend yield N/A
200-day MA $5.16 Market Cap 315.25M

Surface Oncology, Inc. (SURF) Company Bio


Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company’s lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation (CD) 47. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27. The company has a collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is based in Cambridge, Massachusetts.


SURF Latest News Stream


Event/Time News Detail
Loading, please wait...

SURF Latest Social Stream


Loading social stream, please wait...

View Full SURF Social Stream

Latest SURF News From Around the Web

Below are the latest news stories about Surface Oncology Inc that investors may wish to consider to help them evaluate SURF as an investment opportunity.

Surface Oncology +5.8% as Wedbush sees 126% upside

Surface Oncology (SURF) wrapped up after-hours trading up 5.8% after drawing a new Outperform rating from Wedbush. The firm set its price target matching a Street high $12, implying 126% upside. Wall Street analysts are Very Bullish on Surface; it has a Quant Rating of Neutral....

Seeking Alpha | August 28, 2020

3 “Strong Buy” Penny Stocks With Massive Upside Ahead

Penny stocks, you either love them or you hate them. One of the obvious draws of these stocks trading for under $5 per share is the ability to get more bang for your buck. And should these bargain priced stocks see their share prices rise by only a small amount, the rewards can be staggering.However, before jumping right into an investment in a penny stock, Wall Street pros advise looking at the bigger picture and considering other factors beyond just the price tag. For some names that fall into this category, you really do get what you pay for, offering little in the way of long-term growth prospects thanks to weak fundamentals, recent headwinds or even large outstanding share counts.Taking the risk into consideration, we used TipRanks’ database to see if we could find compelling penny...

Yahoo | June 12, 2020

Do Hedge Funds Love Surface Oncology, Inc. (SURF)?

In this article we will take a look at whether hedge funds think Surface Oncology, Inc. (NASDAQ:SURF) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips […]

Yahoo | June 11, 2020

Surface Oncology Announces Change to Location and Format of 2020 Annual Meeting of Stockholders

CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that its 2020 Annual Meeting of Stockholders has been changed to a virtual meeting as a result of continuing concerns surrounding the COVID-19 pandemic. Stockholders will only be able to participate in this year’s Annual Meeting via the virtual meeting. This change is reflective of the public health impact of the COVID-19 pandemic, government restrictions limiting the size of gatherings, and supporting the health and well-being of Surface Oncology’s stockholders, directors and employees, and their communities.

Yahoo | May 28, 2020

Stock Alert: Surface Oncology Shares Up 36% In Premarket

Shares of Surface Oncology (SURF) are up over 36% in pre-market today, after the company announced that it has entered into a clinical trial collaboration with Merck (MRK), known as MSD outside the United States and Canada, through a subsidiary, to evaluate the safety and efficacy of combining Surface's SRF617, an investigational antibody therapy targeting CD39, with Merck's KEYTRUDA (pembrolizumab), the first anti-PD-1 therapy approved in the United States.

RTT News | May 20, 2020

Read More 'SURF' Stories Here

SURF Price Returns

1-mo -19.02%
3-mo 41.94%
6-mo 58.49%
1-year 321.20%
3-year N/A
5-year N/A
YTD 312.23%
2019 -55.66%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7414 seconds.